1. Home
  2. RAND vs HOWL Comparison

RAND vs HOWL Comparison

Compare RAND & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$11.25

Market Cap

34.6M

Sector

Finance

ML Signal

HOLD

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

HOLD

Current Price

$0.78

Market Cap

30.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
HOWL
Founded
1969
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6M
30.7M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
RAND
HOWL
Price
$11.25
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.00
AVG Volume (30 Days)
4.5K
347.2K
Earning Date
03-05-2026
05-07-2026
Dividend Yield
9.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.05
$0.53
52 Week High
$21.30
$2.23

Technical Indicators

Market Signals
Indicator
RAND
HOWL
Relative Strength Index (RSI) 56.02 54.23
Support Level $10.31 $0.56
Resistance Level $12.50 $0.80
Average True Range (ATR) 0.57 0.08
MACD 0.03 0.00
Stochastic Oscillator 82.15 62.56

Price Performance

Historical Comparison
RAND
HOWL

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Share on Social Networks: